Featured News

NICE issues draft “no” on daratumumab novel triplet combination

NICE has issued a draft "no" on the novel triplet combination of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone for the treatment of patients with relapsed or refractory myeloma, for patients in England in Wales.

Read full story

Published
12 July 2018